Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Income from Non-Controlling Interests (2018 - 2021)

Historic Income from Non-Controlling Interests for Sangamo Therapeutics (SGMO) over the last 4 years, with Q2 2021 value amounting to -$5000.0.

  • Sangamo Therapeutics' Income from Non-Controlling Interests rose 8611.11% to -$5000.0 in Q2 2021 from the same period last year, while for Mar 2022 it was -$5000.0, marking a year-over-year increase of 9295.77%. This contributed to the annual value of -$11000.0 for FY2021, which is 9126.98% up from last year.
  • Per Sangamo Therapeutics' latest filing, its Income from Non-Controlling Interests stood at -$5000.0 for Q2 2021, which was up 8611.11% from -$6000.0 recorded in Q1 2021.
  • In the past 5 years, Sangamo Therapeutics' Income from Non-Controlling Interests ranged from a high of $42000.0 in Q3 2020 and a low of -$555000.0 during Q4 2018
  • Moreover, its 4-year median value for Income from Non-Controlling Interests was -$54000.0 (2019), whereas its average is -$84090.9.
  • Over the last 5 years, Sangamo Therapeutics' Income from Non-Controlling Interests had its largest YoY gain of 17777.78% in 2020, and its largest YoY loss of 3148.15% in 2020.
  • Sangamo Therapeutics' Income from Non-Controlling Interests (Quarter) stood at -$555000.0 in 2018, then soared by 90.27% to -$54000.0 in 2019, then tumbled by 31.48% to -$71000.0 in 2020, then skyrocketed by 92.96% to -$5000.0 in 2021.
  • Its last three reported values are -$5000.0 in Q2 2021, -$6000.0 for Q1 2021, and -$71000.0 during Q4 2020.